The criteria for the definition of prediabetes are not unified and whether prediabetes intervention has long-term microvascular and macrovascular benefits is also controversial. However, the harmfulness of intermediate hyperglycemic state between normoglycemia and diabetes is clear. Prediabetes includes impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and a combined form of IFG+ IGT. So far, evidence that early intervention is beneficial for diabetes prevention has been sufficient in the subgroup of IGT but not in that of isolated IFG. Lifestyle intervention, including diet control and physical exercise, is a cornerstone for the management of prediabetes. Pharmacological intervention is only considered for individuals who are difficult to adhere to lifestyle intervention, though having a willing to prevent the disease, or who are allowed by economic condition and are able to benefit from the intervention as judged by doctors. The purpose of identifying prediabetes is to initiate lifestyle intervention and(or) pharmacological intervention to prevent or delay the progression of prediabetes to diabetes or even to delay or avoid chronic diabetic complications. This consensus is aimed to strengthen the concept of diabetes prevention, to identify the key subgroups of prediabetes that should receive the intervention and to know how the intervention is implemented, thereby providing a practical tool for doctors, especially for general practitioners and primary care doctors.